Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Cardiometabolic Disease

In brief

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Key facts

Study ID
NCT06585462
Run by
Amgen
People needed
80
Starts
2024-09-09
Expected to finish
2026-10-01
Last updated by the study team
2026-06-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.